

Yann-Alexandre Vano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6897972/publications.pdf>

Version: 2024-02-01

26
papers

1,435
citations

516710

16
h-index

501196

28
g-index

30
all docs

30
docs citations

30
times ranked

2565
citing authors

#	ARTICLE	IF	CITATIONS
1	Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3031-3040.	7.0	355
2	Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 4416-4428.	7.0	252
3	Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. <i>European Journal of Cancer</i> , 2019, 108, 33-40.	2.8	96
4	PD-L1 Expression and CD8+ T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer. <i>European Urology Focus</i> , 2019, 5, 192-196.	3.1	81
5	Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib. <i>BJU International</i> , 2014, 114, 81-89.	2.5	68
6	Nivolumab, nivolumab+ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 612-624.	10.7	66
7	Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients. <i>PLoS ONE</i> , 2018, 13, e0195042.	2.5	57
8	Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). <i>OncoImmunology</i> , 2015, 4, e1049804.	4.6	51
9	The immune response in cancer: from immunology to pathology to immunotherapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 467, 127-135.	2.8	51
10	Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. , 2022, 10, e004316.		45
11	Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC). <i>Cancers</i> , 2021, 13, 231.	3.7	42
12	BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer. <i>Bulletin Du Cancer</i> , 2020, 107, eS22-eS27.	1.6	37
13	Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e981-e994.	1.9	34
14	Sunitinib in kidney cancer: 10 years of experience and development. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 129-142.	2.4	30
15	Immune-based identification of cancer patients at high risk of progression. <i>Current Opinion in Immunology</i> , 2018, 51, 97-102.	5.5	29
16	Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 350-355.	1.9	26
17	Immune checkpoint inhibitors myocarditis: not all cases are clinically patent. <i>European Heart Journal</i> , 2018, 39, 3553.	2.2	21
18	Update on the most promising biomarkers of response to immune checkpoint inhibitors in clear cell renal cell carcinoma. <i>World Journal of Urology</i> , 2021, 39, 1377-1385.	2.2	15

#	ARTICLE	IF	CITATIONS
19	Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. <i>Cancers</i> , 2020, 12, 1673.	3.7	13
20	Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 523-542.	2.4	11
21	Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO. <i>Bulletin Du Cancer</i> , 2020, 107, eS8-eS15.	1.6	11
22	First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?. <i>Cancers</i> , 2021, 13, 5548.	3.7	11
23	MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7649.	4.1	10
24	NIVOREN GETUG-AFU 26 translational study: Association of PD-1, AXL, and PBRM-1 with outcomes in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N).. <i>Journal of Clinical Oncology</i> , 2020, 38, 618-618.	1.6	8
25	Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals. <i>European Journal of Cancer</i> , 2016, 66, 75-82.	2.8	5
26	Future treatment options in metastatic clear cell renal cell carcinoma. <i>Bulletin Du Cancer</i> , 2022, 109, 2S47-2S58.	1.6	0